Loading
A phase 1 trial of GRN-1201 run by BrightPath Biotherapeutics, completed.
Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma is a phase 1 interventional study registered as NCT02696356 by BrightPath Biotherapeutics, with 18 participants enrolled, started 2016-04. Conditions recorded: Melanoma. Interventions recorded: GRN-1201.
Shares GRN-1201, BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/